E. Fernandez-Cruz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
E. Fernandez-Cruz has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Javier Carbone
Clinical Immunology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
7 shared publications J. Gil
Clinical Immunology Unit, Immunology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
5 shared publicationsJ Navarro
4 shared publicationsJ. Carbone
Servicio de Inmunología Clínica, Hospital General Universitario Gregorio Marañón, Departamento de Microbiología I (Inmunología), Universidad Complutense de Madrid, Madrid, Spain
3 shared publicationsJ. Navarro
Gregorio Marañón Hospital, Immunology, Madrid, Spain
3 shared publicationsA. Villa
Gregorio Marañon Hospital, Cardiology, Madrid, Spain
2 shared publications
Latest Publications
- 1 March 2015
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 43 (2) , 220-222
Audit of the use of intravenous immunoglobulin for antibody deficiencies in a Clinical Immunology Unit
- 1 March 2015
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 43 (2) , 220-222
Audit of the use of intravenous immunoglobulin for antibody deficiencies in a Clinical Immunology Unit
- 1 August 2013
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 14 (4) , 160-164
Flow Cytometry Analysis with a New FITC-Conjugated Monoclonal Antibody-3E12 for HLA-B*57:01 Rapid Screening in Prevention of Abacavir Hypersensitivity in HIV-1–Infected Patients
Rapid screening for the detection of HLA-B*57:01 in the prevention of abacavir hypersensitivity in HIV-1-infected patients is a hallmark for clinical services.
- 1 August 2013
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 14 (4) , 160-164
Flow Cytometry Analysis with a New FITC-Conjugated Monoclonal Antibody-3E12 for HLA-B*57:01 Rapid Screening in Prevention of Abacavir Hypersensitivity in HIV-1–Infected Patients
Rapid screening for the detection of HLA-B*57:01 in the prevention of abacavir hypersensitivity in HIV-1-infected patients is a hallmark for clinical services.
- 1 January 2013
- Vol. 23 (3) , 209-11
High prevalence of allergy-like respiratory diseases in common variable immunodeficiency.
- 1 January 2013
- Vol. 23 (3) , 209-11
High prevalence of allergy-like respiratory diseases in common variable immunodeficiency.
- 27 November 2012
- Published by Wolters Kluwer Health in Transplantation
- Vol. 94 (10S) , 1155
Immune Profiles to Detect Heart Recipients at Risk of Development of Severe Infection
- 27 November 2012
- Published by Wolters Kluwer Health in Transplantation
- Vol. 94 (10S) , 1155
Immune Profiles to Detect Heart Recipients at Risk of Development of Severe Infection
- 31 May 2012
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 94 (1) , 23
Defining risk for recurrent gestational failure by blood natural killer cells subsets
- 31 May 2012
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 94 (1) , 23
Defining risk for recurrent gestational failure by blood natural killer cells subsets
- 1 May 2012
- Published by Wiley in Clinical Transplantation
- Vol. 26 (3) , E277-E283
Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post‐transplant antibody deficiency and severe infections
IgG hypogammaglobulinemia is a risk factor for infection in heart recipients. We assessed reconstitution of humoral immunity after non‐specific intravenous immunoglobulin (IVIg) replacement therapy administered to treat secondary IgG hypogammaglobulinemia in heart recipients with severe infections. The study population comprised 55 heart recipients who were administered IVIg (IVIg group) and 55 heart recipients with no severe infectious complications (control group). An event was defined as a severe infection requiring intravenous drug therapy during the first year after transplantation. The IVIg protocol comprised non‐specific 5% pasteurized IVIg at a dose of 300–400 mg/kg/months. IgG titers were lower in the IVIg group than in controls at seven d (577 vs. 778 mg/dL, p < 0.001) and at one month (553 vs. 684, p = 0.003). After IVIg therapy, IgG concentrations were similar in both groups at three months (681 vs. 737, p = 0.25) and at six months (736 vs. 769, p = 0.46). At three months, the IVIg group had higher levels of antitetanus toxoid and anti‐HBs (ELISA, 2.07 ± 2.11 vs. 0.60 ± 1.24 mg/dL [p = 0.003] and 42 ± 40 vs. 11 ± 31 IU/mL [p = 0.005], respectively) than controls. The mean number of infectious complications was significantly lower after IVIG therapy in the IVIG group. IVIg was associated with restoration of humoral immunity in heart recipients with post‐transplant IgG hypogammaglobulinemia and severe infections.
- 1 May 2012
- Published by Wiley in Clinical Transplantation
- Vol. 26 (3) , E277-E283
Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post‐transplant antibody deficiency and severe infections
IgG hypogammaglobulinemia is a risk factor for infection in heart recipients. We assessed reconstitution of humoral immunity after non‐specific intravenous immunoglobulin (IVIg) replacement therapy administered to treat secondary IgG hypogammaglobulinemia in heart recipients with severe infections. The study population comprised 55 heart recipients who were administered IVIg (IVIg group) and 55 heart recipients with no severe infectious complications (control group). An event was defined as a severe infection requiring intravenous drug therapy during the first year after transplantation. The IVIg protocol comprised non‐specific 5% pasteurized IVIg at a dose of 300–400 mg/kg/months. IgG titers were lower in the IVIg group than in controls at seven d (577 vs. 778 mg/dL, p < 0.001) and at one month (553 vs. 684, p = 0.003). After IVIg therapy, IgG concentrations were similar in both groups at three months (681 vs. 737, p = 0.25) and at six months (736 vs. 769, p = 0.46). At three months, the IVIg group had higher levels of antitetanus toxoid and anti‐HBs (ELISA, 2.07 ± 2.11 vs. 0.60 ± 1.24 mg/dL [p = 0.003] and 42 ± 40 vs. 11 ± 31 IU/mL [p = 0.005], respectively) than controls. The mean number of infectious complications was significantly lower after IVIG therapy in the IVIG group. IVIg was associated with restoration of humoral immunity in heart recipients with post‐transplant IgG hypogammaglobulinemia and severe infections.
- Open Access
- 30 October 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 158 (Supplement) , 60-67
6th International Immunoglobulin Symposium: Poster presentations
Summary: The posters presented at the 6th International Immunoglobulin Symposium covered a wide range of fields and included both basic science and clinical research. From the abstracts accepted for poster presentation, 12 abstracts were selected for oral presentations in three parallel sessions on immunodeficiencies, autoimmunity and basic research. The immunodeficiency presentations dealt with novel, rare class-switch recombination (CSR) deficiencies, attenuation of adverse events following IVIg treatment, association of immunoglobulin (Ig)G trough levels and protection against acute infection in patients with X-linked agammaglobulinaemia (XLA) and common variable immunodeficiency (CVID), and the reduction of class-switched memory B cells in patients with specific antibody deficiency (SAD). The impact of intravenous immunoglobulin on fetal alloimmune thrombocytopenia, pregnancy and postpartum-related relapses in multiple sclerosis and refractory myositis, as well as experiences with subcutaneous immunoglobulin in patients with multi-focal motor neuropathy, were the topics presented in the autoimmunity session. The interaction of dendritic cell (DC)-SIGN and α2,6-sialylated IgG Fc and its impact on human DCs, the enrichment of sialylated IgG in plasma-derived IgG, as wells as prion surveillance and monitoring of anti-measles titres in immunoglobulin products, were covered in the basic science session. In summary, the presentations illustrated the breadth of immunoglobulin therapy usage and highlighted the progress that is being made in diverse areas of basic and clinical research, extending our understanding of the mechanisms of immunoglobulin action and contributing to improved patient care.
- 30 October 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 158 (Supplement) , 60-67
Open Access6th International Immunoglobulin Symposium: Poster presentations
Summary: The posters presented at the 6th International Immunoglobulin Symposium covered a wide range of fields and included both basic science and clinical research. From the abstracts accepted for poster presentation, 12 abstracts were selected for oral presentations in three parallel sessions on immunodeficiencies, autoimmunity and basic research. The immunodeficiency presentations dealt with novel, rare class-switch recombination (CSR) deficiencies, attenuation of adverse events following IVIg treatment, association of immunoglobulin (Ig)G trough levels and protection against acute infection in patients with X-linked agammaglobulinaemia (XLA) and common variable immunodeficiency (CVID), and the reduction of class-switched memory B cells in patients with specific antibody deficiency (SAD). The impact of intravenous immunoglobulin on fetal alloimmune thrombocytopenia, pregnancy and postpartum-related relapses in multiple sclerosis and refractory myositis, as well as experiences with subcutaneous immunoglobulin in patients with multi-focal motor neuropathy, were the topics presented in the autoimmunity session. The interaction of dendritic cell (DC)-SIGN and α2,6-sialylated IgG Fc and its impact on human DCs, the enrichment of sialylated IgG in plasma-derived IgG, as wells as prion surveillance and monitoring of anti-measles titres in immunoglobulin products, were covered in the basic science session. In summary, the presentations illustrated the breadth of immunoglobulin therapy usage and highlighted the progress that is being made in diverse areas of basic and clinical research, extending our understanding of the mechanisms of immunoglobulin action and contributing to improved patient care.
- 10 June 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 157 (Supplement) , 1-2
Mechanisms of action of immune globulin
- 10 June 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 157 (Supplement) , 1-2
Mechanisms of action of immune globulin
- 1 July 2008
- p. 2-6
[Introduction to biological drugs].
Biological therapies have revolutionized the treatment of chronic systemic diseases in which the immune system disorders form a part of the disease mechanism. In these diseases, the patients follow different drug treatments for long periods of time that causes serious adverse reactions and often obtain unsatisfactory efficacy results. Due to the research conducted in the last 10 years, biological drugs have been introduced into the treatment that are aimed against specific targets, such as inflammatory and immunopathological responses that give rise to tissue injury. The new biological therapies have improved the currently available treatments due to greater efficacy, fast action and greater tolerability. The present work aims to provide a global and up-dated view on the biological agents used most in the usual clinical practice and their importance in the management of the chronic immunologically based inflammatory diseases.
- 1 July 2008
- p. 2-6
[Introduction to biological drugs].
Biological therapies have revolutionized the treatment of chronic systemic diseases in which the immune system disorders form a part of the disease mechanism. In these diseases, the patients follow different drug treatments for long periods of time that causes serious adverse reactions and often obtain unsatisfactory efficacy results. Due to the research conducted in the last 10 years, biological drugs have been introduced into the treatment that are aimed against specific targets, such as inflammatory and immunopathological responses that give rise to tissue injury. The new biological therapies have improved the currently available treatments due to greater efficacy, fast action and greater tolerability. The present work aims to provide a global and up-dated view on the biological agents used most in the usual clinical practice and their importance in the management of the chronic immunologically based inflammatory diseases.